These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30265710)

  • 21. Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry.
    Sciria CT; Maddox TM; Marzec L; Rodwin B; Virani SS; Annapureddy A; Freeman JV; O'Hare A; Liu Y; Song Y; Doros G; Zheng Y; Lee JJ; Daggubati R; Vadlamani L; Cannon C; Desai NR
    Clin Cardiol; 2020 Jul; 43(7):743-751. PubMed ID: 32378265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin.
    Pundi KN; Perino AC; Fan J; Schmitt S; Kothari M; Szummer K; Askari M; Heidenreich PA; Turakhia MP
    J Am Heart Assoc; 2021 Dec; 10(23):e020904. PubMed ID: 34779243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.
    Pandya EY; Bajorek B
    Patient; 2017 Apr; 10(2):163-185. PubMed ID: 27438598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees.
    Wong ES; Done N; Zhao M; Woolley AB; Prentice JC; Mull HJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1056-1066. PubMed ID: 34337995
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
    Maura G; Pariente A; Alla F; Billionnet C
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
    Brais C; Larochelle J; Turgeon MH; Blais L; Farand P; Perreault S; Letemplier G; Beauchesne MF
    J Pharm Pharm Sci; 2017; 20():8-14. PubMed ID: 28459661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study.
    Salmasi S; Safari A; Kapanen A; Adelakun A; Kwan L; MacGillivray J; Andrade JG; Deyell MW; Loewen P
    Res Social Adm Pharm; 2022 Nov; 18(11):3920-3928. PubMed ID: 35753963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
    Mueller T; Alvarez-Madrazo S; Robertson C; Bennie M
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1378-1386. PubMed ID: 28752670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of a Pharmacist-Led Educational Interventional Program on Electronic Monitoring-assessed Adherence to Direct Oral Anticoagulants: A Randomized, Controlled Trial in Patients with Nonvalvular Atrial Fibrillation.
    Shiga T; Kimura T; Fukushima N; Yoshiyama Y; Iwade K; Mori F; Ajiro Y; Haruta S; Yamada Y; Sawada E; Hagiwara N;
    Clin Ther; 2022 Nov; 44(11):1494-1505. PubMed ID: 36244853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Charlton A; Vidal X; Sabaté M; Bailarín E; Martínez LML; Ibáñez L
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1210-1220. PubMed ID: 34464214
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-Term Medication Adherence Trajectories to Direct Oral Anticoagulants and Clinical Outcomes in Patients With Atrial Fibrillation.
    An J; Bider Z; Luong TQ; Cheetham TC; Lang DT; Fischer H; Reynolds K
    J Am Heart Assoc; 2021 Nov; 10(21):e021601. PubMed ID: 34713708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation.
    Moudallel S; van den Bemt BJF; Zwikker H; de Veer A; Rydant S; Dijk LV; Steurbaut S
    Patient Educ Couns; 2021 Jan; 104(1):155-162. PubMed ID: 32622691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.